INTRODUCTION:

Vaccination is the only practical tool to stop the expansion and eradicate the COVID-19 pandemic, most vaccines have demonstrated the ability to induce immune responses. It is predictable that there are several vaccines with different levels of protection, so their use will depend in each country on the health authorities and recommendations of the World Health Organization (WHO).

OBJECTIVE:

To determine the Adverse Events (ESAVIS) of the Sinopharm vaccine administered to adults at the mass vaccination point of the Health Network No. 4 ESTE of the city of La Paz, from April to October, 2021.

MATERIAL AND METHODS:

A descriptive, observational study was carried out, a sample of60 cases, with a diagnosis of Events Supposedly attributable to vaccination and/or immunization. The methods used were documentary analysis, instruments used ESAVIS files from the Ministry of Health and Sports. Sociodemographic data, sex and age were collected.

RESULTS:

The people who presented adverse events to the Sinopharm Vaccine are 78.3% female with an average age of 44 years, with a pathological history of Systemic Arterial Hypertension in 5%, the medication administered in 83.3% is oxygen, the most frequent symptom is dizziness 58.3%, more mild ESAVIS occurred in 98.3%.

CONCLUSION:

People who received the Sinopharm vaccine have Mild ESAVIS.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )